← back to search

Rugang Zhang

The University of Texas MD Anderson Cancer Center · US
Area of research
Molecular Biology · Cancer Research
Research interest
Research interests include Epigenetics and DNA Methylation, Chromatin Remodeling and Cancer, Histone Deacetylase Inhibitors Research, and Protein Degradation and Inhibitors.
h-index
61
citations
13,066
works
502
NIH funding
primary concept
Biology
email

Recent publications

ADAR1 downregulation by autophagy drives senescence independently of RNA editing by enhancing p16INK4a levels
Nature Cell Biology 2022cited by 58position: lastdoi
The FENDRR/FOXC2 Axis Contributes to Multidrug Resistance in Gastric Cancer and Correlates With Poor Prognosis
Frontiers in Oncology 2021cited by 19position: middledoi
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
Nature Communications 2020cited by 364position: middledoi
Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy
Journal of Clinical Investigation 2020cited by 198position: middledoi
NAD+ metabolism governs the proinflammatory senescence-associated secretome
Nature Cell Biology 2019cited by 388position: lastdoi
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference
Cancer 2019cited by 53position: middledoi
Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers
Cancer Cell 2018cited by 272position: middledoi
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
Cell Reports 2016cited by 428position: lastdoi
RETRACTED ARTICLE: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance
Nature 2016cited by 390position: middledoi
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
Nature Medicine 2015cited by 677position: lastdoi
Comprehensive analysis of the ubiquitinome during oncogene-induced senescence in human fibroblasts
Cell Cycle 2015cited by 28position: lastdoi
SUZ12 Promotes Human Epithelial Ovarian Cancer by Suppressing Apoptosis via Silencing HRK
Molecular Cancer Research 2012cited by 82position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Andrew V. Kossenkov · University of Pittsburgh4 papers (2015–2022)Benjamin G. Bitler · University of Colorado Boulder3 papers (2015–2020)David W. Speicher · The Wistar Institute3 papers (2015–2019)Hengrui Zhu · Fudan University2 papers (2015–2016) · 2 papers (2015–2016)Katherine M. Aird · Pennsylvania State University2 papers (2015–2019)José R. Conejo-García · Duke University2 papers (2015–2016)Hsin‐Yao Tang · The Wistar Institute2 papers (2015–2019)D. Schultz · California University of Pennsylvania2 papers (2015–2019) · 1 papers (2020–2020)Mark A. Morgan · University of Arizona Cancer Center1 papers (2018–2018)Timothy A. Chan · Cleveland Clinic1 papers (2020–2020)Meixiao Long · The Ohio State University1 papers (2018–2018)Eric J. Brown · University of Pennsylvania1 papers (2020–2020)Kathleen T. Montone · The Ohio State University1 papers (2018–2018)David G. Huntsman · Huntsman Marine Science Centre1 papers (2020–2020)Lili Zhao · Children’s Hospital of Fudan University Xiamen Branch1 papers (2020–2020)Weiping Zou · University of Michigan1 papers (2020–2020) · 1 papers (2016–2016)Wei Li · Union Hospital1 papers (2020–2020)